Publications by authors named "Amaya Gasco Hernandez"
Unlabelled: Outcomes for patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are poor, with median overall survival (OS) ranging from 6 to 18 months. For those who progress on standard-of-care (chemo)immunotherapy, treatment options are limited, necessitating the development of rational therapeutic strategies. Toward this end, we targeted the key HNSCC drivers PI3K-mTOR and HRAS via the combination of tipifarnib, a farnesyltransferase (FTase) inhibitor, and alpelisib, a PI3Kα inhibitor, in multiple molecularly defined subsets of HNSCC.
View Article and Find Full Text PDFUnlabelled: Despite some notable successes, there are still relatively few agents approved for cancer prevention. Here we review progress thus far in the development of medicines for cancer prevention, and we outline some key concepts that could further enable or accelerate drug development for cancer prevention in the future. These are summarized under six key themes: (i) unmet clinical need, (ii) patient identification, (iii) risk stratification, (iv) pharmacological intervention, (v) clinical trials, and (vi) health care policy.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the effectiveness of combining a DNA vaccine (MEDI0457) targeting HPV-16/18 with the PD-L1 inhibitor durvalumab in treating recurrent/metastatic HPV-associated head and neck cancer.
- Of the 35 patients treated, the overall response rate (ORR) was 27.6%, with some patients achieving complete responses, though responses were not influenced by PD-L1 expression levels.
- While the primary efficacy goal wasn't fully met, the treatment was well tolerated, and significant increases in HPV-specific T cells were observed, suggesting potential clinical benefits.